Relmada Therapeutics, Inc. announced that Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology ended on September 3, 2026. Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for urological diseases.

Relmada Therapeutics reported a net loss of $12.9 million ($0.11 per share) for the quarter ended June 30, 2026, with research and development expenses rising to $8.4 million. The company holds $217.7 million in cash and short-term investments as of June 30, 2026, which management expects will fund operations through 2029, including the completion of the Phase 3 RESCUE program for NDV-01. Relmada plans to file Investigational New Drug applications for both NDV-01 and sepranolone by year-end 2026, with Phase 3 and Phase 2 trials expected to initiate upon clearance. Additionally, Bipin Dalmia was appointed Chief Business Officer, and the company was added to the Russell 2000 and Russell 3000 indexes effective June 26, 2026. Relmada Therapeutics is a clinical-stage biotechnology company developing therapies for oncology and central nervous system disorders.

Relmada Therapeutics, Inc. announced the appointment of Bipin Dalmia, PhD, MBA, as its new Chief Business Officer on July 28, 2026. Dalmia brings nearly three decades of biopharmaceutical leadership experience, including roles at Ferring Pharmaceuticals, Biolex Therapeutics, Syngenta, and Novartis, with specific expertise in corporate strategy, business development, and non-muscle invasive bladder cancer (NMIBC). He will report directly to CEO Sergio Traversa and lead the company's commercial planning and strategic initiatives as it advances its lead candidate, NDV-01, toward late-stage development. Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders.